Caudal type homeobox 2 (CDX2) (CDX2)

Caudal type homeobox 2 (CDX2) is a homeodomain-containing transcription factor that serves as a master regulator of intestinal development and differentiation (UniProt: P41229). It is essential for the specification of the intestinal phenotype, where it controls the expression of various genes involved in nutrient absorption and mucosal integrity, such as MUC2 and sucrase-isomaltase. In clinical oncology, CDX2 is a well-established tumor suppressor in the colon; its loss is a strong predictor of poor outcomes in colorectal cancer patients and is linked to epithelial-mesenchymal transition and increased metastatic potential (Dalerba et al., N Engl J Med, 2016). Interestingly, while its loss is detrimental in the gut, its ectopic expression is a hallmark of Barrett's esophagus and is associated with leukemogenesis in acute myeloid leukemia (Scholl et al., J Exp Med, 2007). Pharmacological interest in CDX2 promoter activity focuses on identifying compounds that can reactivate its expression in deficient tumors to promote cell cycle arrest and differentiation. Current research explores the use of epigenetic modulators, such as histone deacetylase (HDAC) inhibitors like Vorinostat, and the targeting of the Vitamin D Receptor (VDR) pathway to influence CDX2 levels (Coskun et al., J Biol Chem, 2011). Restoring CDX2 activity represents a promising strategy for 'differentiation therapy' in aggressive colorectal cancers.

Other names

CDX-2CDX3Caudal-type homeobox protein 2

Induction of CDX2 expression via epigenetic modification (e.g., HDAC inhibition) or activation of upstream nuclear receptors (e.g., VDR) to restore intestinal differentiation and tumor suppression.